Lmcg Investments LLC Has $9.18 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lmcg Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 231.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 14,481 shares of the biopharmaceutical company’s stock after buying an additional 10,110 shares during the quarter. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $9,184,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Gilman Hill Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.9% during the 1st quarter. Gilman Hill Asset Management LLC now owns 5,303 shares of the biopharmaceutical company’s stock worth $3,363,000 after buying an additional 100 shares during the last quarter. Portside Wealth Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 7.6% during the 1st quarter. Portside Wealth Group LLC now owns 776 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 55 shares during the last quarter. Whipplewood Advisors LLC raised its stake in Regeneron Pharmaceuticals by 3,220.0% in the 1st quarter. Whipplewood Advisors LLC now owns 166 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 161 shares in the last quarter. Merit Financial Group LLC raised its stake in Regeneron Pharmaceuticals by 87.7% in the 1st quarter. Merit Financial Group LLC now owns 1,629 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 761 shares in the last quarter. Finally, NBC Securities Inc. acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $78,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of Regeneron Pharmaceuticals stock opened at $484.93 on Thursday. The firm has a market capitalization of $52.36 billion, a PE ratio of 12.67, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $575.25 and its 200 day moving average is $661.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $481.58 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the firm earned $9.55 earnings per share. The company’s revenue was down 3.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Wall Street Analyst Weigh In

REGN has been the subject of several analyst reports. Bank of America dropped their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. UBS Group dropped their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Finally, Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $847.40.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.